Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
(Celecoxib + valacyclovir hydrochloride) by Dogwood Therapeutics for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID): Likelihood of Approval
(Celecoxib + valacyclovir hydrochloride) is under clinical development by Dogwood Therapeutics and currently in Phase II for Post-Acute Sequelae of...